The East African Single Dossier and What It Means for Buyers

The East African Community joint assessment lets a manufacturer submit one medicines dossier, have it reviewed once by assessors from seven national regulators, and receive a regional recommendation — after which each country still decides registration for itself ^[3]. The EAC's own procedural guideline is explicit that pharmaceutical products in the region are regulated by the individual partner states' authorities, and that importers must be licensed before they trade ^[1]. The single dossier harmonises the assessment. It does not harmonise the border.

For a buyer that distinction is the whole article. The route changes which finished medicines end up registered in Tanzania, Uganda, Kenya and their neighbours, and therefore which can be imported on an ordinary permit. It does nothing for laboratory reagents or research material, which never enter it, and it creates no regional import permit. The country articles in this cluster cover the permits; this one covers the regional layer above them.

The procedure and who takes part

The joint assessment runs under the EAC Medicines Regulatory Harmonisation programme. A 2022 evaluation by the participating authorities names seven: the Tanzania Medicines and Medical Devices Authority as lead, Uganda's National Drug Authority, Kenya's Pharmacy and Poisons Board, the Rwanda Food and Drugs Authority, Burundi's regulator ABREMA, South Sudan's Drug and Food Control Authority, and the Zanzibar Medicines and Medical Devices Authority ^[3]. The EAC publishes the shared rulebook as a compendium of guidelines covering dossier format, stability, therapeutic equivalence, labelling, naming, GMP and procedural aspects, alongside a procedure for joint assessment and accelerated national registration ^[2].

The dossier is the EAC Common Technical Document, Modules I to V, submitted in English; anything in another language needs a certified or notarised English translation, and responsibility for applying rests with the marketing authorisation holder ^[1].

The same guideline sets the baseline the joint route is measured against. A national authority screens a dossier for completeness within 30 working days and rejects an incomplete one outright; evaluation is to be completed within 12 months, or six months for priority products; applicants have 180 calendar days to answer first-round queries and 120 days for later rounds, and an application may not run to more than four rounds ^[1]. Products already registered by agreed benchmark agencies qualify for abridged evaluation ^[1]. Those are the national clocks a supplier faces if it applies country by country instead.

One assessment, several registrations

The member-country evaluation describes a nine-step sequence ^[3]. The indicative timings below are the procedure's targets as reported there, not guarantees.

The same study reports that the joint process cut registration timelines from around 24 months to 8–12 months in its pilot phase, and that the median time for joint assessment had fallen to 240 working days by 2019 ^[3]. As of December 2021 the programme had received 159 applications, assessed 144 and recommended 79 products ^[4].

Two separate clocks

The joint clock stops at the recommendation; the national clock starts there. Companies surveyed reported a median of 30 to 90 days from positive recommendation to marketing authorisation, but some said that in certain countries a positive recommendation did not directly result in national approval, with authorities requesting further information after the joint review ^[4]. They also reported separate national registration fees, no central submission or tracking system, and country-specific requirements surfacing after the regional decision ^[4].

Each national decision then runs on the ordinary EAC procedural rules: registration is valid for five years, renewal is applied for at least three months before expiry, retention fees are payable to each authority, and a cancellation or suspension by one authority is notified to all partner states ^[1]. The registration a buyer depends on is therefore a national one, with a national expiry date, even when the assessment behind it was regional.

What it changes for a supplier, and what it changes for a buyer

For a supplier of finished medicines the gain is real: one dossier and one scientific review instead of seven, and a shorter route to several markets ^[3][4]. The costs of national fees, national queries and national renewals remain ^[1][4].

For a buyer, the route only matters once a product is registered in the country where the goods will land, because every national import regime in the region checks registration at the border. Tanzania's guideline requires imported pharmaceutical products to be registered by TMDA unless specially approved, and issues a permit per shipment ^[5]. Uganda requires a verification certificate for every consignment before importation ^[6]. Kenya's rules bar import of an unregistered health product or technology ^[7]. Suppliers sometimes describe a product as "EAC-approved"; ask instead for the registration number in your country, and be clear on the difference between approved, registered and merely listed before you accept a document as evidence.

Where it does not apply

• Laboratory reagents and chemicals. The procedure concerns marketing authorisation of pharmaceutical products; raw materials and chemicals fall outside it ^[1][4].
• Research material not intended for the market. There is no dossier to assess and no marketing authorisation holder to apply.
• Investigational products. Tanzania, for example, issues import permits for them only against its own clinical trial approval ^[5].
• Unregistered-product special permits, which each authority grants under its own national rules ^[5][6].
• Import clearance. None of the documents describes a regional import permit; each national guideline requires its own per-consignment authorisation ^[5][6].

That last point is why one country's rules do not travel to the next, even inside a harmonisation programme. Assessment is shared; enforcement at the border is not.

Joint assessment against importing into each state separately

Read the table from the buyer's side and the conclusion is plain: every row that touches a consignment stays national ^[1][5][6]. Use the regional route as a reason a finished product may already be registered where you are, and nothing more. For everything else, the country article for your border is the one to work from.

How a buyer should use the route

1. Establish whether the item is a registered finished product at all. If it is laboratory material, skip the regional route and go straight to the national permit or chemicals regime ^[1][5].
2. If it is a finished product, ask the supplier for its registration certificate and number in the destination country, with the expiry date ^[1].
3. Check that registration is current on the date the permit or certificate will be reviewed, not only on the order date; Uganda reviews status on the date of verification ^[6].
4. Do not assume a registration in one partner state covers another. Each authority registers separately and can decide differently ^[3][4].
5. Keep the registration evidence in the consignment file alongside the national import permit, so the inspector sees both documents together ^[5][6].